Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Hepatitis

  Free Subscription


Articles published in Clin Infect Dis

Retrieve available abstracts of 113 articles:
HTML format
Text format



Single Articles


    August 2019
  1. PEAK CM, Stous SS, Healy JM, Hofmeister MG, et al
    Homelessness and Hepatitis A - San Diego County, 2016-2018.
    Clin Infect Dis. 2019 Aug 15. pii: 5550168. doi: 10.1093.
    PubMed     Text format     Abstract available


  2. STEVENS ER, Nucifora KA, Hagan H, Jordan AE, et al
    Cost-effectiveness of direct anti-viral agents for hepatitis C virus infection and a combined intervention of syringe access and medication assisted therapy for opioid use disorders in an injection drug use population.
    Clin Infect Dis. 2019 Aug 11. pii: 5546014. doi: 10.1093.
    PubMed     Text format     Abstract available


  3. SUN L, Fan J, Gao H, Shan L, et al
    Background End-stage Liver Diseases but not Pure HBV Infection Exacerbate Clinical Outcomes in Patients with Acute Hepatitis E.
    Clin Infect Dis. 2019 Aug 1. pii: 5542442. doi: 10.1093.
    PubMed     Text format    


    July 2019
  4. SAFREED-HARMON K, Blach S, Aleman S, Boe Kielland K, et al
    The Consensus Hepatitis C Cascade of Care: standardized reporting to monitor progress toward elimination.
    Clin Infect Dis. 2019 Jul 28. pii: 5540024. doi: 10.1093.
    PubMed     Text format     Abstract available


  5. SHING JZ, Ly KN, Xing J, Teshale EH, et al
    Prevalence of Hepatitis B Virus Infection among US Adults Aged 20-59 Years with a History of Injection Drug Use: National Health and Nutrition Examination Survey, 2001-2016.
    Clin Infect Dis. 2019 Jul 27. pii: 5539881. doi: 10.1093.
    PubMed     Text format     Abstract available


  6. AKIYAMA MJ, Lipsey D, Heo M, Agyemang L, et al
    Low Hepatitis C Reinfection Following Direct-Acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy.
    Clin Infect Dis. 2019 Jul 26. pii: 5538954. doi: 10.1093.
    PubMed     Text format     Abstract available


  7. SPRINGER SA
    HCV reinfection is low among persons who use drugs maintained on medication treatment for Opioid Use Disorder.
    Clin Infect Dis. 2019 Jul 26. pii: 5538956. doi: 10.1093.
    PubMed     Text format    


  8. ARTENIE AA, Cunningham EB, Dore GJ, Conway B, et al
    Patterns of drug, alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies: An international s
    Clin Infect Dis. 2019 Jul 11. pii: 5531892. doi: 10.1093.
    PubMed     Text format     Abstract available


  9. COOPER C
    Eliminating Hepatitis C (and the Unknowns) in the HIV Co-Infected.
    Clin Infect Dis. 2019 Jul 2. pii: 5527234. doi: 10.1093.
    PubMed     Text format    


    June 2019
  10. WADE AJ, Doyle JS, Gane E, Stedman C, et al
    Outcomes of treatment for hepatitis C in primary care compared to hospital-based care: a randomised controlled trial in people who inject drugs.
    Clin Infect Dis. 2019 Jun 22. pii: 5522438. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. KING H, Xing J, Dean HD, Holtzman D, et al
    Trends in prevalence of protective levels of hepatitis B surface antibody among adults aged 18-49 years with risk factors for hepatitis B virus infection-United States, 2003-2014.
    Clin Infect Dis. 2019 Jun 20. pii: 5522094. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. LIN KY, Sun HY, Chen YH, Lo YC, et al
    Effect of a hepatitis A vaccination campaign during a hepatitis A outbreak in Taiwan, 2015-2017: a modeling study.
    Clin Infect Dis. 2019 Jun 3. pii: 5510337. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2019
  13. MACDONALD BR, Chu TC, Stewart RA, Ojha RP, et al
    Setting-Based Prioritization for Birth Cohort Hepatitis C Virus Testing in the United States.
    Clin Infect Dis. 2019 May 24. pii: 5498354. doi: 10.1093.
    PubMed     Text format    


  14. SHIMAKAWA Y, Ndow G, Njie R, Njai HF, et al
    Hepatitis B core-related antigen (HBcrAg): an alternative to HBV DNA to assess treatment eligibility in Africa.
    Clin Infect Dis. 2019 May 17. pii: 5491470. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. GUTKIND S, Schackman BR, Morgan JR, Leff JA, et al
    Cost-effectiveness of HCV Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs.
    Clin Infect Dis. 2019 May 16. pii: 5490664. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. ASSOUMOU SA, Tasillo A, Vellozzi C, Yazdi GE, et al
    Cost-effectiveness and budgetary impact of HCV testing, treatment and linkage to care in U.S. prisons.
    Clin Infect Dis. 2019 May 16. pii: 5490662. doi: 10.1093.
    PubMed     Text format     Abstract available


  17. HARRINGTON PR, Komatsu TE, Sun H, Naeger LK, et al
    HCV RNA Levels Following Virologic Failure with Direct-Acting Antivirals: Implications for Lower Sensitivity Diagnostic Assays.
    Clin Infect Dis. 2019 May 10. pii: 5487938. doi: 10.1093.
    PubMed     Text format     Abstract available


  18. TOYODA H, Tada T, Yasuda S, Mizuno K, et al
    Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Who Achieved Sustained Virologic Response.
    Clin Infect Dis. 2019 May 6. pii: 5485915. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2019
  19. BUTT AA, Yan P, Aslam S, Shaikh OS, et al
    Hepatitis C Virus Treatment with Directly Acting Agents Reduces the Risk of Incident Diabetes - Results from ERCHIVES.
    Clin Infect Dis. 2019 Apr 12. pii: 5448895. doi: 10.1093.
    PubMed     Text format     Abstract available


  20. YOUNOSSI ZM, Stepanova M, Jacobson I, Muir AJ, et al
    Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening of Patient-Reported Outcomes.
    Clin Infect Dis. 2019 Apr 5. pii: 5428146. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. BERTISCH B, Brezzi M, Negro F, Mullhaupt B, et al
    Very low hepatitis C viral loads in treatment-naive persons: do they compromise hepatitis C virus antigen testing?
    Clin Infect Dis. 2019 Apr 3. pii: 5426964. doi: 10.1093.
    PubMed     Text format     Abstract available


  22. MATHUR P, Kottilil S
    Hepatitis C core antigen testing: Still an effective diagnostic method for global elimination of hepatitis C.
    Clin Infect Dis. 2019 Apr 3. pii: 5426965. doi: 10.1093.
    PubMed     Text format    


  23. SORIANO V, Gomez-Gallego F, Corral O
    Hepatitis delta estimates in the United States revisited.
    Clin Infect Dis. 2019 Apr 3. pii: 5426967. doi: 10.1093.
    PubMed     Text format    


    March 2019
  24. SALVADORI N, Fan B, Teeyasoontranon W, Ngo-Giang-Huong N, et al
    Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus.
    Clin Infect Dis. 2019 Mar 29. pii: 5422240. doi: 10.1093.
    PubMed     Text format     Abstract available


  25. GANE E, Poordad F, Zadeikis N, Valdes J, et al
    Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease.
    Clin Infect Dis. 2019 Mar 28. pii: 5421746. doi: 10.1093.
    PubMed     Text format     Abstract available


  26. KISER JJ
    Safety of Hepatitis C Viral Protease Inhibitors in Compensated Cirrhotics: Lingering Concerns Put to Rest?
    Clin Infect Dis. 2019 Mar 28. pii: 5421743. doi: 10.1093.
    PubMed     Text format    


  27. NAGGIE S, Fierer DS, Hughes MD, Kim AY, et al
    Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.
    Clin Infect Dis. 2019 Mar 28. pii: 5421820. doi: 10.1093.
    PubMed     Text format     Abstract available


  28. LUI GCY, Wong NS, Wong RYK, Tse YK, et al
    Antiviral therapy for hepatitis B prevents liver injury in patients with tuberculosis and hepatitis B co-infection.
    Clin Infect Dis. 2019 Mar 22. pii: 5421304. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2019
  29. BOETTIGER DC, Salazar-Vizcaya L, Dore GJ, Gray RT, et al
    Can Australia reach the World Health Organization Hepatitis C elimination goal by 2025 among HIV-positive gay and bisexual men?
    Clin Infect Dis. 2019 Feb 28. pii: 5366676. doi: 10.1093.
    PubMed     Text format     Abstract available


  30. GEDDES L, Iversen J, Wand H, Esmaeili A, et al
    Sex discrepancies in the protective effect of opioid agonist therapy on incident hepatitis C infection.
    Clin Infect Dis. 2019 Feb 28. pii: 5366653. doi: 10.1093.
    PubMed     Text format     Abstract available


  31. CHEN SH, Lai HC, Chiang IP, Su WP, et al
    Performance of Acoustic Radiation Force Impulse Elastography for Staging Liver Fibrosis in Patients with Chronic Hepatitis C after Viral Eradication.
    Clin Infect Dis. 2019 Feb 28. pii: 5366592. doi: 10.1093.
    PubMed     Text format     Abstract available


  32. RAMIERE C, Charre C, Miailhes P, Bailly F, et al
    Patterns of HCV transmission in HIV-infected and HIV-negative men having sex with men.
    Clin Infect Dis. 2019 Feb 27. pii: 5365873. doi: 10.1093.
    PubMed     Text format     Abstract available


  33. BROUWER WP, Chan HL, Lampertico P, Hou J, et al
    Genome Wide Association Study Identifies Genetic Variants Associated With Early And Sustained Response To (Peg)Interferon In Chronic Hepatitis B Patients: The GIANT-B Study.
    Clin Infect Dis. 2019 Feb 2. pii: 5305981. doi: 10.1093.
    PubMed     Text format     Abstract available


  34. CHAUDHURY CS, Mee T, Chairez C, McLaughlin M, et al
    Testosterone in Men With Chronic Hepatitis C Infection and After Hepatitis C Viral Clearance.
    Clin Infect Dis. 2019 Feb 2. pii: 5305922. doi: 10.1093.
    PubMed     Text format     Abstract available


  35. BROWN TT
    Hypogonadism in Men With Hepatitis C: What Is a Clinician to Do?
    Clin Infect Dis. 2019 Feb 2. pii: 5305923. doi: 10.1093.
    PubMed     Text format    


    January 2019
  36. CHAILLON A, Rand EB, Reau N, Martin NK, et al
    Cost-Effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in The United States.
    Clin Infect Dis. 2019 Jan 28. pii: 5303781. doi: 10.1093.
    PubMed     Text format     Abstract available


  37. MCAULEY JB, Close R
    Better Guidance on Treating HCV in Pregnancy: The Time is Now.
    Clin Infect Dis. 2019 Jan 7. pii: 5275237. doi: 10.1093.
    PubMed     Text format    


  38. BRESKIN A, Westreich D, Hurt CB, Cole SR, et al
    The effects of hepatitis C treatment eligibility criteria on all-cause mortality among people with HIV.
    Clin Infect Dis. 2019 Jan 7. pii: 5274661. doi: 10.1093.
    PubMed     Text format     Abstract available


  39. PATEL EU, Thio CL, Boon D, Thomas DL, et al
    Prevalence of Hepatitis B and Hepatitis D Virus Infections in the United States, 2011-2016.
    Clin Infect Dis. 2019 Jan 3. pii: 5272449. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2018
  40. LOOMBA R, Decaris M, Li KW, Shankaran M, et al
    Discovery of half-life of circulating HBsAg in patients with chronic hepatitis B infection using heavy water labeling.
    Clin Infect Dis. 2018 Dec 24. pii: 5259172. doi: 10.1093/cid/ciy1100.
    PubMed     Text format     Abstract available


    October 2018
  41. TALAL AH, Andrews P, Mcleod A, Chen Y, et al
    Integrated, Co-located, Telemedicine-based Treatment Approaches for Hepatitis C Virus (HCV) Management in Opioid Use Disorder Patients on Methadone.
    Clin Infect Dis. 2018 Oct 17. pii: 5133592. doi: 10.1093.
    PubMed     Text format     Abstract available


  42. BRESKIN A, Westreich D, Cole SR, Hudgens MG, et al
    The Effects of Hepatitis C Infection and Treatment on All-cause Mortality Among People Living With Human Immunodeficiency Virus.
    Clin Infect Dis. 2018 Oct 12. pii: 5128783. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2018
  43. TIO SY, Nickless D, McCracken J, Nedumannil R, et al
    A Man With Tonsillitis and Hepatitis.
    Clin Infect Dis. 2018;67:1303-1305.
    PubMed     Text format    


  44. LAI JC, Wong GL, Yip TC, Tse YK, et al
    Chronic Hepatitis B Increases Liver-Related Mortality of Patients With Acute Hepatitis E: A Territorywide Cohort Study From 2000 to 2016.
    Clin Infect Dis. 2018;67:1278-1284.
    PubMed     Text format     Abstract available


  45. PATEL EU, Mehta SH, Boon D, Quinn TC, et al
    Limited Coverage of Hepatitis C Virus Testing in the United States, 2013-2017.
    Clin Infect Dis. 2018 Sep 15. pii: 5098442. doi: 10.1093.
    PubMed     Text format     Abstract available



  46. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.
    Clin Infect Dis. 2018 Sep 12. pii: 5095352. doi: 10.1093.
    PubMed     Text format     Abstract available


  47. JHAVERI R, Broder T, Bhattacharya D, Peters MG, et al
    Universal Screening of Pregnant Women for Hepatitis C: The Time Is Now.
    Clin Infect Dis. 2018 Sep 12. pii: 5095353. doi: 10.1093.
    PubMed     Text format     Abstract available


    August 2018
  48. BUTT AA, Yan P, Lo Re V 3rd, Shaikh OS, et al
    Trends in Treatment Uptake and Provider Specialty for HCV Infection in the VA Healthcare System: Results from ERCHIVES.
    Clin Infect Dis. 2018 Aug 22. pii: 5077936. doi: 10.1093.
    PubMed     Text format     Abstract available


  49. SULKOWSKI MS
    The Proof Is in the Patient: Hepatitis C Virus Microelimination in the Swiss Human Immunodeficiency Virus Cohort Study.
    Clin Infect Dis. 2018 Aug 13. pii: 5071944. doi: 10.1093.
    PubMed     Text format    


  50. BRAUN DL, Hampel B, Martin E, Kouyos R, et al
    High Number of Potential Transmitters Revealed in a Population-based Systematic Hepatitis C Virus RNA Screening Among Human Immunodeficiency Virus-infected Men Who Have Sex With Men.
    Clin Infect Dis. 2018 Aug 13. pii: 5071946. doi: 10.1093.
    PubMed     Text format     Abstract available


  51. BRAUN DL, Hampel B, Kouyos R, Nguyen H, et al
    High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men.
    Clin Infect Dis. 2018 Aug 13. pii: 5071945. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2018
  52. BIXLER D, Zhong Y, Ly KN, Moorman AC, et al
    Mortality among Patients with Chronic Hepatitis B (CHB) Infection: the Chronic Hepatitis Cohort Study (CHeCS).
    Clin Infect Dis. 2018 Jul 28. pii: 5061152. doi: 10.1093.
    PubMed     Text format     Abstract available


  53. SMITH D, Huynh C, Moore AJ, Frick A, et al
    Herd Immunity Likely Protected the Men who have Sex with Men in Recent Hepatitis A Outbreak in San Diego CA.
    Clin Infect Dis. 2018 Jul 25. pii: 5059685. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2018
  54. KILMER GA, Barker LK, Ly KN, Jiles RB, et al
    Hepatitis B vaccination and screening among foreign-born women of reproductive age in the United States: 2013-2015.
    Clin Infect Dis. 2018 Jun 1. pii: 5026244. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2018
  55. HOSRY J, Angelidakis G, Kaseb A, Jiang Y, et al
    Inhibition of Hepatitis C Virus Replication Induced by Chemotherapy: A Prospective Observational Study.
    Clin Infect Dis. 2018 May 15. pii: 4996053. doi: 10.1093.
    PubMed     Text format    


  56. ALROY-PREIS S, Daly ER, Adamski C, Dionne-Odom J, et al
    Large Outbreak of Hepatitis C Virus Associated With Drug Diversion by a Healthcare Technician.
    Clin Infect Dis. 2018 May 14. pii: 4995993. doi: 10.1093.
    PubMed     Text format     Abstract available


  57. MEISSNER EG
    The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression?
    Clin Infect Dis. 2018 May 1. pii: 4989914. doi: 10.1093.
    PubMed     Text format    


  58. INOUE T, Nakayama J, Moriya K, Kawaratani H, et al
    Gut Dysbiosis Associated With Hepatitis C Virus Infection.
    Clin Infect Dis. 2018 May 1. pii: 4989908. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2018
  59. HECTOR J, Vinikoor M, Chilengi R, Ehmer J, et al
    No Impact of Hepatitis B Virus Infection on Early Mortality among HIV-infected Patients in Southern Africa.
    Clin Infect Dis. 2018 Apr 18. pii: 4975531. doi: 10.1093.
    PubMed     Text format    


  60. LEE YL, Chen GJ, Chen NY, Liou BH, et al
    Less Severe but Prolonged Course of Acute Hepatitis A in HIV-positive Patients than HIV-negative Patients During an Outbreak: A Multicenter Observational Study.
    Clin Infect Dis. 2018 Apr 17. pii: 4972863. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2018
  61. WALKER A, Boyce A, Geller G, Thio CL, et al
    Direct Acting Antivirals and Hepatitis C: The Ethics of Price and Rationing by Genotype.
    Clin Infect Dis. 2018 Mar 29. pii: 4956154. doi: 10.1093.
    PubMed     Text format    


  62. ROCKSTROH JK, Lacombe K, Viani RM, Orkin C, et al
    Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected with Hepatitis C Virus and Human Immunodeficiency Virus-1: the EXPEDITION-2 Study.
    Clin Infect Dis. 2018 Mar 16. pii: 4939381. doi: 10.1093.
    PubMed     Text format     Abstract available


  63. BARTLETT SR, Fox P, Cabatingan H, Jaros A, et al
    Demonstration of near-elimination of hepatitis C virus among a prison population: the Lotus Glen Correctional Centre hepatitis C treatment project.
    Clin Infect Dis. 2018 Mar 12. pii: 4930770. doi: 10.1093.
    PubMed     Text format     Abstract available


  64. KLEINSTEIN SE, Shea PR, Stamm LM, Sulkowski M, et al
    Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial.
    Clin Infect Dis. 2018 Mar 7. pii: 4705930. doi: 10.1093/cid/cix1051.
    PubMed     Text format     Abstract available


  65. MOGALIAN E, Stamm LM, Osinusi A, Brainard DM, et al
    Drug-Drug Interactions Studies between HCV Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted HIV Antiretroviral Regimens in Healthy Volunteers.
    Clin Infect Dis. 2018 Mar 7. pii: 4924529. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2018
  66. BAROCAS JA, Tasillo A, Eftekhari Yazdi G, Wang J, et al
    Population level outcomes and cost-effectiveness of expanding the recommendation for age-based hepatitis C testing in the United States.
    Clin Infect Dis. 2018 Feb 6. pii: 4840186. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2018
  67. TROPPY S, Soliva S, Onofrey S, DeMaria A Jr., et al
    Geographic Disparities in Access to Syringe Services Programs Among Young Persons with Hepatitis C Virus Infection in Massachusetts.
    Clin Infect Dis. 2018 Jan 31. pii: 4831117. doi: 10.1093.
    PubMed     Text format    


    December 2017
  68. HUA S, Vigano S, Tse S, Zhengyu O, et al
    Pegylated IFN-alpha-induced NK cell activation is associated with HIV-1 DNA decline in ART-treated HIV-1/HCV co-infected patients.
    Clin Infect Dis. 2017 Dec 20. pii: 4767848. doi: 10.1093/cid/cix1111.
    PubMed     Text format     Abstract available


  69. YOUNOSSI ZM, Stepanova M, Asselah T, Foster G, et al
    Hepatitis C in Patients with Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes.
    Clin Infect Dis. 2017 Dec 20. pii: 4766885. doi: 10.1093/cid/cix1106.
    PubMed     Text format     Abstract available


  70. RICKLES M, Rebeiro PF, Sizemore L, Juarez P, et al
    Tennessee's In-State Vulnerability Assessment for a 'Rapid Dissemination of HIV or HCV Infection' Event Utilizing Data about the Opioid Epidemic.
    Clin Infect Dis. 2017 Dec 7. pii: 4706246. doi: 10.1093/cid/cix1079.
    PubMed     Text format     Abstract available


  71. KAPADIA SN, Jeng PJ, Schackman BR, Bao Y, et al
    State Medicaid hepatitis C treatment eligibility criteria and use of direct acting antivirals.
    Clin Infect Dis. 2017 Dec 1. pii: 4682615. doi: 10.1093/cid/cix1062.
    PubMed     Text format     Abstract available


    November 2017
  72. BOEREKAMPS A, Newsum AM, Smit C, Arends JE, et al
    High treatment uptake in HIV/HCV-coinfected patients after unrestricted access to direct-acting antivirals in the Netherlands.
    Clin Infect Dis. 2017 Nov 23. pii: 4654728. doi: 10.1093/cid/cix1004.
    PubMed     Text format     Abstract available


  73. ROCKSTROH JK
    Is HCV elimination in well-defined patient groups possible?
    Clin Infect Dis. 2017 Nov 23. pii: 4654730. doi: 10.1093/cid/cix1010.
    PubMed     Text format    


  74. BOEREKAMPS A, Van den Berk GE, Fanny LN, Leyten EM, et al
    Declining HCV incidence in Dutch HIV positive men who have sex with men after unrestricted access to HCV therapy.
    Clin Infect Dis. 2017 Nov 23. pii: 4654729. doi: 10.1093/cid/cix1007.
    PubMed     Text format     Abstract available


  75. BEDIMO RJ, Adams-Huet B, Poindexter J, Brown G, et al
    The Differential Effects of HIV and HCV on Bone Micro-Architecture and Fracture risk.
    Clin Infect Dis. 2017 Nov 14. doi: 10.1093/cid/cix1011.
    PubMed     Text format     Abstract available


    October 2017
  76. DE LEDINGHEN V, Laforest C, Hezode C, Pol S, et al
    Retreatment with sofosbuvir plus grazoprevir/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed a NS5A or NS3-containing regimen. ANRS HC34 REVENGE.
    Clin Infect Dis. 2017 Oct 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  77. YAYA I, Costa M, Marcellin F, Miailhes P, et al
    Gender, alcohol use and fibrosis in HIV-HCV co-infected individuals.
    Clin Infect Dis. 2017 Oct 23. doi: 10.1093.
    PubMed     Text format    


  78. PARR JB, Lodge EK, Holzmayer V, Pepin J, et al
    An Efficient, Large-Scale Survey of Hepatitis C Viremia in the Democratic Republic of the Congo Using Dried Blood Spots.
    Clin Infect Dis. 2017 Oct 18. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2017
  79. BUTT AA, Yan P, Simon TG, Abou-Samra AB, et al
    Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVES.
    Clin Infect Dis. 2017;65:1006-1011.
    PubMed     Text format     Abstract available


  80. HASHEM M, Jhaveri R, Saleh DA, Sharaf SA, et al
    Spontaneous Viral Load Decline and Subsequent Clearance of Chronic Hepatitis C Virus in Postpartum Women Correlates With Favorable Interleukin-28B Gene Allele.
    Clin Infect Dis. 2017;65:999-1005.
    PubMed     Text format     Abstract available


  81. ASSOUMOU SA, Tasillo A, Leff JA, Schackman BR, et al
    The cost-effectiveness of one-time hepatitis C screening strategies among adolescents and young adults in primary care settings.
    Clin Infect Dis. 2017 Sep 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  82. CHHATWAL J
    Hepatitis C screening: From modeling to public health policy.
    Clin Infect Dis. 2017 Sep 9. doi: 10.1093.
    PubMed     Text format    


  83. LIU CH, Chen YS, Wang SS, Liu CJ, et al
    Sofosbuvir-based interferon-free direct acting antiviral regimens for heart transplant recipients with chronic hepatitis C virus infection.
    Clin Infect Dis. 2017 Sep 4. doi: 10.1093.
    PubMed     Text format     Abstract available


  84. WEINBERG EM, Reddy KR
    Let's Make a Deal: Shortening the solid organ transplant waiting time in exchange for transmitting and treating Hepatitis C infection in the era of safe and effective DAAs.
    Clin Infect Dis. 2017 Sep 4. doi: 10.1093.
    PubMed     Text format    


    August 2017
  85. ESMAEILI A, Mirzazadeh A, Morris MD, Hajarizadeh B, et al
    The effect of female sex on hepatitis C incidence among people who inject drugs: results from the international multi-cohort InC3 Collaborative.
    Clin Infect Dis. 2017 Aug 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  86. ABRAHAM GM, Spooner LM
    Citius Altius Fortius: The New Paradigm In The Treatment Of Chronic Hepatitis C Disease.
    Clin Infect Dis. 2017 Aug 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  87. KOUAME GM, Boyd A, Moh R, Badje A, et al
    Higher mortality despite early ART in HIV and hepatitis B virus coinfected patients with high HBV replication.
    Clin Infect Dis. 2017 Aug 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  88. WANG H, Wan Z, Xu R, Guan Y, et al
    A Novel Human Pegivirus HPgV-2 (HHpgV-1) is Tightly Associated with HCV Infection and HCV/HIV-1 Co-Infection.
    Clin Infect Dis. 2017 Aug 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  89. KELLY EM, Dodge JL, Bacchetti P, Sarkar M, et al
    Moderate Alcohol use is not Associated with Fibrosis Progression in HIV/HCV Co-Infected Women: A Prospective Cohort Study.
    Clin Infect Dis. 2017 Aug 16. doi: 10.1093.
    PubMed     Text format     Abstract available


  90. LO RE V 3RD
    Is Moderate Alcohol Consumption Safe for HIV/Hepatitis C Virus-Coinfected Women?
    Clin Infect Dis. 2017 Aug 16. doi: 10.1093.
    PubMed     Text format    


  91. BYRNE DD, Tate JP, Forde KA, Lim JK, et al
    Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status.
    Clin Infect Dis. 2017 Aug 16. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2017
  92. SARKAR M, Dodge JL, Greenblatt RM, Kuniholm MH, et al
    Reproductive Aging and Hepatic Fibrosis Progression in HIV/Hepatitis C Virus Co-Infected Women.
    Clin Infect Dis. 2017 Jul 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  93. POWDERLY WG, Naggie S, Kim AY, Vargas HE, et al
    IDSA/AASLD response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C.
    Clin Infect Dis. 2017 Jul 17. doi: 10.1093.
    PubMed     Text format    


    June 2017
  94. CHI H, Wong D, Peng J, Cao J, et al
    Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation.
    Clin Infect Dis. 2017 Jun 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2017
  95. KIM AY
    The National Academy Report on the Elimination of Viral Hepatitis: An Infectious Disease Physician's Perspective.
    Clin Infect Dis. 2017 May 27. doi: 10.1093.
    PubMed     Text format    


  96. FELD JJ, Ramji A, Shafran SD, Willems B, et al
    Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.
    Clin Infect Dis. 2017 May 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  97. ZUCMAN D, Farfour E, Mazaux L, Hillaire S, et al
    How to face the outbreak of viral hepatitis A in men-who-have-sex-with-men in France without vaccines?
    Clin Infect Dis. 2017 May 16. doi: 10.1093.
    PubMed     Text format    


  98. BOSCHI C, Colson P, Tissot-Dupont H, Bernit E, et al
    Hepatitis C virus relapse 78 weeks after completion of successful direct acting therapy.
    Clin Infect Dis. 2017 May 16. doi: 10.1093.
    PubMed     Text format    


  99. MOON J, Hyland RH, Zhang F, Brainard DM, et al
    Efficacy and safety of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C in persons with sickle cell disease.
    Clin Infect Dis. 2017 May 13. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2017
  100. ROSENBERG ES, Hall EW, Sullivan PS, Sanchez TH, et al
    Estimation of State-Level Prevalence of Hepatitis C Virus Infection, US States and District of Columbia, 2010.
    Clin Infect Dis. 2017 Apr 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  101. OZARAS R, Balkan II, Yemisen M, Mete B, et al
    Reactivation of Hepatitis B Virus Following Treatment of Hepatitis C Virus Infection in Coinfected Patients.
    Clin Infect Dis. 2017 Apr 24. doi: 10.1093.
    PubMed     Text format    


  102. BUTT AA, Yan P, Chew KW, Currier J, et al
    Risk of Acute Myocardial Infarction Among HCV+ and HCV- Men at Various Lipid Levels: Results from ERCHIVES.
    Clin Infect Dis. 2017 Apr 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  103. TIEN PC
    HCV-associated Alterations in Lipid and Lipoprotein levels: Helpful or Harmful to the Heart?
    Clin Infect Dis. 2017 Apr 24. doi: 10.1093.
    PubMed     Text format    


  104. CANARY L, Hariri S, Campbell C, Young R, et al
    Geographic disparities in access to syringe services programs among young people with hepatitis C virus infection in the U.S.
    Clin Infect Dis. 2017 Apr 11. doi: 10.1093.
    PubMed     Text format     Abstract available


  105. MORRIS MD, Shiboski S, Bruneau J, Hahn JA, et al
    Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration.
    Clin Infect Dis. 2017;64:860-869.
    PubMed     Text format     Abstract available


  106. NOSKA AJ, Belperio PS, Loomis TP, O'Toole TP, et al
    Prevalence of HIV, HCV and HBV among Homeless and Non-homeless United States Veterans.
    Clin Infect Dis. 2017 Apr 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2017
  107. WYLES D, Brau N, Kottilil S, Daar ES, et al
    Sofosbuvir and Velpatasvir for the Treatment of HCV in Patients Coinfected with HIV-1: an Open-Label, Phase 3 Study.
    Clin Infect Dis. 2017 Mar 29. doi: 10.1093.
    PubMed     Text format     Abstract available


  108. BUTT AA, Ren Y, Lo Re V 3rd, Taddei T, et al
    Comparing Child-Pugh, MELD and FIB-4 to Predict Clinical Outcomes in HCV-Infected Persons: Results from ERCHIVES.
    Clin Infect Dis. 2017 Mar 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  109. CEPEDA JA, Thomas DL, Astemborski J, Sulkowski MS, et al
    Increased mortality among persons with chronic hepatitis C with moderate or severe liver disease: a cohort study.
    Clin Infect Dis. 2017 Mar 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  110. HEZODE C, Fourati S, Chevaliez S, Scoazec G, et al
    Sofosbuvir-Daclatasvir-Simeprevir plus Ribavirin in Direct-Acting Antiviral-Experienced Hepatitis C Patients.
    Clin Infect Dis. 2017 Mar 10. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  111. NAGGIE S, Marks KM, Hughes M, Fierer DS, et al
    Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.
    Clin Infect Dis. 2017 Feb 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  112. VINIKOOR MJ, Sinkala E, Chilengi R, Mulenga L, et al
    Impact of antiretroviral therapy on liver fibrosis among HIV-infected adults with and without HBV coinfection in Zambia.
    Clin Infect Dis. 2017 Feb 4. doi: 10.1093.
    PubMed     Text format    


    August 2016
  113. WITTKOP L
    Endstage liver disease in HIV infection: an avoidable burden?
    Clin Infect Dis. 2016.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: